Integra LifeSciences Holdings Updates Presentation on 2026 Refinancing

What Happened

• Integra LifeSciences Holdings Corporation filed a Form 8-K on September 8, 2026 (Item 7.01) to furnish an updated investor presentation (Exhibit 99.1).
• The presentation may be used in discussions with existing or prospective lenders in connection with the company’s previously disclosed plans to refinance its outstanding senior credit facility in 2026.
• The report was signed by Lea Knight, Executive Vice President and Chief Financial Officer.

Key Details

• Filing date: September 8, 2026.
• Exhibit: Investor Presentation dated September 8, 2026 (furnished as Exhibit 99.1).
• Purpose: Used for presentations to lenders regarding refinancing the company’s outstanding senior credit facility in 2026.
• Regulatory item: Disclosure furnished under Item 7.01 (Regulation FD Disclosure).

Why It Matters

• This filing signals active preparations to refinance Integra’s senior credit facility, which is a key part of the company’s capital structure and could affect its interest costs, debt maturities, and liquidity profile.
• Investors should watch for subsequent disclosures with terms of any refinancing (interest rates, maturity, covenants or fees), because those details can influence leverage, credit metrics and cash flow needs.
• No terms or financial specifics of a new facility were included in this 8-K—only an updated investor presentation was furnished.